JP6753706B2 - 水素ガス発生装置 - Google Patents
水素ガス発生装置 Download PDFInfo
- Publication number
- JP6753706B2 JP6753706B2 JP2016118169A JP2016118169A JP6753706B2 JP 6753706 B2 JP6753706 B2 JP 6753706B2 JP 2016118169 A JP2016118169 A JP 2016118169A JP 2016118169 A JP2016118169 A JP 2016118169A JP 6753706 B2 JP6753706 B2 JP 6753706B2
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen gas
- metal rod
- superheated steam
- gas
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 title claims description 160
- 239000007789 gas Substances 0.000 claims description 74
- 238000010438 heat treatment Methods 0.000 claims description 71
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- 239000002184 metal Substances 0.000 claims description 23
- 229910052751 metal Inorganic materials 0.000 claims description 23
- 238000000605 extraction Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 5
- 229910000831 Steel Inorganic materials 0.000 claims description 4
- 229910001220 stainless steel Inorganic materials 0.000 claims description 4
- 239000010935 stainless steel Substances 0.000 claims description 4
- 239000010959 steel Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 78
- 229910052742 iron Inorganic materials 0.000 description 39
- 210000002966 serum Anatomy 0.000 description 30
- 210000003556 vascular endothelial cell Anatomy 0.000 description 25
- 102100031375 Endothelial lipase Human genes 0.000 description 22
- 101710087274 Endothelial lipase Proteins 0.000 description 22
- 206010028980 Neoplasm Diseases 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 18
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 17
- 230000009471 action Effects 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 16
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 14
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 14
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 14
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 14
- 102100023472 P-selectin Human genes 0.000 description 12
- 238000001816 cooling Methods 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 11
- 102100033467 L-selectin Human genes 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 230000002757 inflammatory effect Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 230000002792 vascular Effects 0.000 description 10
- 238000012795 verification Methods 0.000 description 10
- 208000023275 Autoimmune disease Diseases 0.000 description 8
- 102100032912 CD44 antigen Human genes 0.000 description 8
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 8
- 102100023471 E-selectin Human genes 0.000 description 8
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 8
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 8
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 8
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 8
- 238000007689 inspection Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 7
- 206010020751 Hypersensitivity Diseases 0.000 description 7
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 7
- 108010092694 L-Selectin Proteins 0.000 description 7
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 7
- 239000000090 biomarker Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 6
- 229910002651 NO3 Inorganic materials 0.000 description 6
- 108010035766 P-Selectin Proteins 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- -1 nitrate ions Chemical class 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 208000035473 Communicable disease Diseases 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 101000622123 Homo sapiens E-selectin Proteins 0.000 description 5
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 5
- 206010052779 Transplant rejections Diseases 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 5
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000033115 angiogenesis Effects 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 102000004890 Interleukin-8 Human genes 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000004968 inflammatory condition Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000011810 insulating material Substances 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 102000009088 Angiopoietin-1 Human genes 0.000 description 3
- 108010048154 Angiopoietin-1 Proteins 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 108010024212 E-Selectin Proteins 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 108010031801 Lipopolysaccharide Receptors Proteins 0.000 description 3
- 102000005482 Lipopolysaccharide Receptors Human genes 0.000 description 3
- 206010000891 acute myocardial infarction Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 3
- 229940096397 interleukin-8 Drugs 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000017525 heat dissipation Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 101710102499 Alanine and proline-rich secreted protein Apa Proteins 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010028778 Complement C4 Proteins 0.000 description 1
- 102100025877 Complement component C1q receptor Human genes 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 101000933665 Homo sapiens Complement component C1q receptor Proteins 0.000 description 1
- 208000001911 Idiopathic aplastic anemia Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- 102000016551 L-selectin Human genes 0.000 description 1
- GWNVDXQDILPJIG-SHSCPDMUSA-N Leukotriene C4 Natural products CCCCCC=C/CC=C/C=C/C=C/C(SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)C(O)CCCC(=O)O GWNVDXQDILPJIG-SHSCPDMUSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000010836 Lymphocyte Homing Receptors Human genes 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical group C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000011242 molecular targeted therapy Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 238000000899 pressurised-fluid extraction Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 1
- 230000009441 vascular protection Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/30—Hydrogen technology
- Y02E60/36—Hydrogen production from non-carbon containing sources, e.g. by water electrolysis
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
(2)また、実施形態の一態様に係る水素ガス発生装置は、上記(1)の構成において、前記第1の金属棒は、前記原水に浸かる一方、前記第2の金属棒は、前記原水に接触しない位置に設けられることを特徴とする。
(sCD69)の検証結果について説明する。
(b)透析+0.1〜0.3Vol%の濃度の水素ガスを含む蒸気混合ガスの吸入90分後。
(c)透析のみ行った直後(蒸気混合ガスの吸入無し)。
5 ガス取出部
10 水素ガス発生装置
14 右側壁(第1の側壁)
15 後壁(第2の側壁)
17 角部
31 加熱パイプ
55 空気取入部
400 キャップ体
Claims (6)
- 原水が流入する加熱パイプを有し、前記原水を加熱して過熱蒸気を発生させ、この過熱蒸気をさらに加熱して水素ガスを含む蒸気混合ガスを生成する過熱蒸気加熱部と、
前記蒸気混合ガスと前記過熱蒸気とを含む混合流体から気液分離し、分離された前記蒸気混合ガスを取り出すガス取出部と、を備えるとともに、
前記加熱パイプは、
酸化し易い金属棒により構成された酸化促進部材を収容しており、当該酸化促進部材は、ステンレスにより形成された第1の金属棒と、鉄鋼材により形成され、前記第1の金属棒よりも小径の第2の金属棒とを備え、前記第2の金属棒は、前記第1の金属棒よりも相対的に短く形成され、複数本束ねられており、
前記ガス取出部から取り出された前記蒸気混合ガスに含まれる前記水素ガスの濃度を、4.2Vol%未満とした
ことを特徴とする水素ガス発生装置。 - 前記第1の金属棒は、前記原水に浸かる一方、前記第2の金属棒は、前記原水に接触しない位置に設けられることを特徴とする請求項1に記載の水素ガス発生装置。
- 生成した前記蒸気混合ガスに外気を取り込み、前記水素ガスを希釈する空気取入部を備える
ことを特徴とする請求項1または2に記載の水素ガス発生装置。 - 前記空気取入部は、孔径が0.5〜1.0mmのピンホールを有する
ことを特徴とする請求項3に記載の水素ガス発生装置。 - 前記過熱蒸気加熱部は、当該加熱パイプの上端開口に前記空気取入部を構成するキャップ体を取付けた
ことを特徴とする請求項3または4に記載の水素ガス発生装置。 - 前記水素ガスの濃度を、0.1〜0.3Vol%とした
ことを特徴とする請求項1〜5のいずれか一つに記載の水素ガス発生装置。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015137151 | 2015-07-08 | ||
JP2015137151 | 2015-07-08 | ||
JP2015199405 | 2015-10-07 | ||
JP2015199405 | 2015-10-07 | ||
JP2015237707 | 2015-12-04 | ||
JP2015237707 | 2015-12-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017105692A JP2017105692A (ja) | 2017-06-15 |
JP6753706B2 true JP6753706B2 (ja) | 2020-09-09 |
Family
ID=59058799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016118169A Active JP6753706B2 (ja) | 2015-07-08 | 2016-06-14 | 水素ガス発生装置 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6753706B2 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11305249B2 (en) | 2018-04-19 | 2022-04-19 | Friend Co., Ltd. | Hydrogen mixed gas generation apparatus |
WO2019234922A1 (ja) * | 2018-06-08 | 2019-12-12 | フレンド株式会社 | 水素混合ガスの生成方法 |
WO2021064995A1 (ja) * | 2019-10-04 | 2021-04-08 | フレンド株式会社 | 水素混合ガスの生体への効能の評価方法および評価システム |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4490349A (en) * | 1981-08-17 | 1984-12-25 | Beeston Company Limited | Hydrogen production |
JP2006179276A (ja) * | 2004-12-22 | 2006-07-06 | Nitto Denko Corp | 水素ガス発生ユニットの加熱システム及び電磁誘導加熱ユニット及び水素ガス発生システム |
WO2008151367A1 (en) * | 2007-06-12 | 2008-12-18 | Alternative Energy International Ltd | A system for production of hydrogen |
JP2013151400A (ja) * | 2012-01-26 | 2013-08-08 | Yasutane Takato | 水素ガス発生装置 |
JP5091364B1 (ja) * | 2012-06-04 | 2012-12-05 | ミズ株式会社 | 生体用水素ガス供給装置 |
JP2014061275A (ja) * | 2012-08-31 | 2014-04-10 | Hiromaito Co Ltd | 水素ガス吸引方法並びに装置 |
JP5502973B1 (ja) * | 2012-11-30 | 2014-05-28 | ミズ株式会社 | 生体用高濃度水素ガス供給装置 |
WO2015045118A1 (ja) * | 2013-09-27 | 2015-04-02 | フレンド株式会社 | 水素ガス発生装置 |
WO2015155848A1 (ja) * | 2014-04-09 | 2015-10-15 | フレンド株式会社 | 水素ガス発生装置 |
-
2016
- 2016-06-14 JP JP2016118169A patent/JP6753706B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2017105692A (ja) | 2017-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6753706B2 (ja) | 水素ガス発生装置 | |
CN204709378U (zh) | 一种无烟艾灸仪 | |
JP6563399B2 (ja) | 無効発汗促進装置 | |
CN106176188B (zh) | 一种多功能中药熏蒸治疗仪 | |
CN205783393U (zh) | 一种前出风式负离子空气净化器 | |
CN204786765U (zh) | 用于工业控制室的新风系统 | |
CN108355212A (zh) | 一种小儿内科用雾化吸入装置 | |
Madabhavi et al. | Paraneoplastic Raynaud’s phenomenon manifesting before the diagnosis of lung cancer | |
JP6749171B2 (ja) | 吸入ガスの効能検証方法 | |
Yang et al. | Selenadiazole derivative-loaded metal azolate frameworks facilitate NK cell immunotherapy by sensitizing tumor cells and shaping immuno-suppressive microenvironments | |
Tuuminen et al. | Dampness and mold hypersensitivity syndrome and vaccination as risk factors for chronic fatigue syndrome | |
CN210277934U (zh) | 一种呼吸内科输氧呼吸面罩 | |
Jayaranagaiah et al. | Malignant pleural mesothelioma presenting with cardiac tamponade-a rare case report and review of the literature | |
JP7305635B2 (ja) | 水素混合ガスの生成方法 | |
CN208525398U (zh) | 气体自动跟踪阻挡物的上升回流装置及艾灸理疗设备 | |
Jayeshkumar et al. | Nebulization Therapy for Lung Cancer | |
CN2801186Y (zh) | 一种感冒治疗器 | |
CN108392708A (zh) | 一种耳鼻喉科消毒给药器 | |
CN208611246U (zh) | 一种泌尿外科中卧躺式治疗装置 | |
Zuyderduyn et al. | Cigarette Smoke Extract Affects Release Of IL-8 And SLPI In Differentiated Primary Bronchial Epithelial Cell Cultures (PBEC) From COPD Versus Controls | |
CN211273808U (zh) | 一种乳腺外科用中药过滤装置 | |
CN211024594U (zh) | 一种可多体位使用的口哨式雾化器 | |
Ahn et al. | Primary tracheal small cell carcinoma treated by concurrent chemoradiotherapy | |
CN209075335U (zh) | 一种内分泌治疗用辅助装置 | |
Lee et al. | Iron Deficiency Anemia due to Long-time Bloodletting Using Cupping. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AA64 | Notification of invalidation of claim of internal priority (with term) |
Free format text: JAPANESE INTERMEDIATE CODE: A241764 Effective date: 20160712 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190326 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200220 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200303 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200415 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200811 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200820 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6753706 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |